AVXL

Anavex is a clinical-stage CNS drug developer that, by its own admission in the 10-K, is 'in the pre-revenue stage and have not earned any revenues since our inception in 2004.' There is no business to value on fundamentals: FY2025 net loss was -$46.4M, operating loss -$51.4M, and the accumulated deficit has grown to -$382M. ROE of -48.9% is a mechanical artifact of a company that only spends. Every conventional profitability and growth lens fails here — this is a binary bet on the pipeline (ANAVEX 2-73/blarcamesine in Alzheimer's, Parkinson's and Rett, plus ANAVEX 3-71 in schizophrenia), not on a P/E.

What keeps this a hold rather than an avoid is the balance sheet, which is unusually clean for a cash-burning biotech. FY2025 shows $103M cash against just $8.95M total liabilities — a liabilities/equity ratio of 0.09x and essentially no debt. At ~$39M of annual operating cash burn that is roughly 2.5 years of runway, and cash of ~$1.15/share backstops a meaningful share of the $2.76 price. Management is also spending less: operating expenses fell to $51.4M from $52.9M and R&D dropped to $37.6M from $41.8M as the ATTENTION-AD (Alzheimer's) and EXCELLENCE (Rett) trials wound down, with spend rotating toward ANAVEX 3-71. The MD&A's reference to manufacturing 2-73 'to support the MAA' signals an active EU marketing application — the single most important near-term catalyst.